DxTerity

About:

DxTerity focuses on simplifying genomic testing, facilitating quantitative analysis of genomic bio-markers.

Website: http://dxterity.com

Twitter/X: dxterityinc

Description:

DxTerity Diagnostics is focused on simplifying genomic testing -- bringing the power of personalized medicine to routine medical care. The DxTerity technology, DxDirectTM, is a simple, fast and affordable technique for analysis of complex gene signatures. DxDirectTM combines a robust chemical ligation process, NEATTM , and a unique sample stabilization system, DxCollectTM. This enable direct from whole blood or tissue sample multiplex gene expression testing without many of the constraints that exist today. Testing which once could only be done by a sophisticated research lab, or highly specialized and high skilled area within a clinical lab, can now be performed reliably in a routine manner by lab technicians and clinicians, all with the same level of quality. Specialties-Molecular Diagnostics, Oncology, Immune Response

Total Funding Amount:

$3.79M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Rancho Dominguez, California, United States

Founded Date:

2006-01-01

Contact Email:

info(AT)DxTerity.com

Founders:

Bob Terbrueggen

Number of Employees:

11-50

Last Funding Date:

2021-10-13

IPO Status:

Private

Industries:

© 2025 bioDAO.ai